Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus GG + bifidobacterium animalis subsp. lactis BB-12 + inulin + oligofructose
- Development stage
- Unknown
- Lead developer
- Novonesis
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This synbiotic formulation is a combination of two well-characterized probiotic bacterial strains, *Lactobacillus rhamnosus* GG (LGG) and *Bifidobacterium animalis* subsp. *lactis* BB-12, paired with the prebiotic fibers inulin and oligofructose. The formulation is designed to synergistically enhance gut health by providing live beneficial bacteria alongside selective substrates that promote their growth and activity. Clinical studies, including the EU-funded SYCAN project, have investigated this combination for its ability to modulate the gut microbiota, improve intestinal barrier function, and stimulate systemic immune responses. Research has specifically targeted the reduction of colorectal cancer risk markers, the prevention of polyp recurrence, and the enhancement of immune function in elderly populations and stressed individuals (e.g., college students). The synbiotic has demonstrated the capacity to increase natural killer cell activity and the production of key cytokines like interferon-gamma and interleukin-2.
- Other names
- LGG + BB-12 + inulin + oligofructosesynbiotic formulation (LGG, BB-12, inulin, oligofructose)
02
Targets
IFNG (Interferon gamma)IL-2 (Interleukin 2)
Beyond the preview
Go deeper on lactobacillus rhamnosus GG + bifidobacterium animalis subsp. lactis BB-12 + inulin + oligofructose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus GG + bifidobacterium animalis subsp. lactis BB-12 + inulin + oligofructose.